不同药物对高血压患者血尿酸影响的对比研究

目的 ]比较应用氯沙坦 /氢氯噻嗪固定复方制剂与苯那普利合用或不合用氢氯噻嗪治疗高血压的疗效、安全性以及对血尿酸的影响。 方法 ]5 6例老年高血压患者 ,分入氯沙坦 /氢氯噻嗪组(A)和苯那普利 (B)组 ,每组病人 2 8例 ,每天分别予氯沙坦 /氢氯噻嗪固定复方制剂 5 0mg/ 12 .5mg和苯那普利 10mg ,B组患者血压控制不理想加用氢氯噻嗪 12 .5mg ,用药 4周。用药前后测定血压、血尿酸 ,并监测有无药物相关不良反应。 结果 ]两组用药 4周后血压均明显降低 ,没有显著差异 (P >0 .0 5 )。但A组不良反应少于B组 (P <0 .0 1) ,而且氯沙坦 /氢氯噻嗪固定复方制剂组患者血尿酸增高水平明显低于苯那普利合用氢氯噻嗪组 (P <0 .0 1)。 结论 ]氯沙坦 /氢氯噻嗪固定复方制剂对老年高血压患者降压疗效与苯那普利合用氢氯噻嗪相似 ,但对血尿酸影响更小 ,有更好的安全性和耐受性。

Effect different medicine on serum uric acid in patients with hypertension

Objective To compare the effect, safety and influence on the serum uric acid of the combined therapy with hydrochlorothiazide (HCT) and Losatan or Benazepril in the treatment of hypertension. Method] Fifty-six aged patients with hypertension were randomly and evenly divided into Group A and Group B. The patients of Group A received Losartan 50 mg and HCT 12.5 mg qd; the patients of Group B received Benazepril 10 mg qd. If the blood pressure was still in high level, the patients of Group B received Benazepril 10 mg and HCT 12.5 mg qd. Blood pressure was measured every week. The changes of blood pressure and the serum uric acid in the end of week 4 were measured. Adverse reaction was evaluated as indicis of safety. Results] The decrease in mean diastolic pressure and systolic pressure on week 4 in Group A and Group B did not differ significantly (P>0.05). However, the drug related adverse reactions were significantly fewer in Group A than that in Group B(P<0.01). Furthermore, the increase of the serum uric acid were significantly lower in Group A (P<0.01). Conclusions] The antihypertensive efficacy of Losartan vs HCT is similar to that of the combination of Benazepril and HCT in aged patients with hypertension. However, the effect on the serum uric acid is fewer in Group A received Losartan vs HCT. It means the safety and tolerability of the former is better than the latter.